Several large studies have found that heavy, prolonged use of diphenhydramine, the active ingredient in Benadryl, is associated with a higher risk of developing dementia. The connection is not unique to Benadryl itself but runs through a broader class of drugs called anticholinergics, of which diphenhydramine is one of the strongest. The risk appears to climb with cumulative dose over years, which means the occasional tablet for a bee sting or a bad allergy day is a very different story from nightly use as a sleep aid.
What the Largest Studies Found
The study that put this question on the map followed more than 3,400 older adults for an average of about seven years. Over that time, roughly one in four participants developed dementia. Those who had accumulated the highest lifetime exposure to strong anticholinergic drugs, including diphenhydramine, had about a 54 percent greater risk of dementia and a 63 percent greater risk of Alzheimer’s disease compared to people who had not used these medications at all.1JAMA Internal Medicine. Cumulative Use of Strong Anticholinergics and Incident Dementia: A Prospective Cohort Study The researchers saw a clear dose-response pattern: as total lifetime exposure went up, so did the risk. People in the lowest exposure category showed no meaningful increase in dementia risk, while those in the middle tiers showed a modest elevation. The sharpest jump appeared only at the highest cumulative doses.
A more recent study, published in 2024, zeroed in specifically on first-generation antihistamines like diphenhydramine among patients with allergic rhinitis. It found a similar dose-dependent pattern. At the lowest cumulative dose level, the hazard ratio was about 1.13. At the highest, it climbed to roughly 1.51, meaning the heaviest users had about 50 percent higher odds of developing dementia compared to non-users.2PubMed. Cumulative Dose Effects of H1 Antihistamine Use on the Risk of Dementia in Patients With Allergic Rhinitis Both studies share an important limitation: they are observational. They can show that people who use these drugs more tend to develop dementia more often, but they cannot definitively prove the drugs caused the dementia. People who take more Benadryl might also have chronic sleep problems, anxiety, or other health issues that independently raise dementia risk. Researchers try to adjust for those factors statistically, but it is impossible to account for every variable.
Why Diphenhydramine Gets Special Attention
Not all medications block the brain chemical acetylcholine to the same degree. Researchers have developed rating scales that rank drugs by their “anticholinergic burden,” and diphenhydramine consistently lands in the highest category.3PubMed Central. Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: a systematic review It shares that top tier with certain older antidepressants, bladder medications, and antipsychotics. Many people do not realize that the allergy pill in their medicine cabinet has the same anticholinergic punch as prescription drugs their doctor would think twice about prescribing to an older adult.
Acetylcholine plays a central role in memory formation, attention, and learning. When a drug blocks it across the brain, the short-term effects are familiar to anyone who has felt groggy after taking Benadryl: drowsiness, foggy thinking, and sometimes confusion. The worry among researchers is that when that blockade happens repeatedly over years, the short-term cognitive fog may shade into lasting damage. That is what the epidemiological data seem to point toward, though the exact mechanism is still being investigated.
What Anticholinergics Do to the Brain
Brain imaging studies have added a biological layer to the statistical findings. One study using PET and MRI scans found that cognitively normal older adults who were taking anticholinergic medications had lower brain metabolism and greater brain shrinkage in regions critical for memory, particularly the medial temporal lobe and the cortex. The researchers proposed that reduced cholinergic activity from these drugs may trigger synaptic loss and neurodegeneration in areas with heavy cholinergic wiring.4PubMed Central. Association Between Anticholinergic Medication Use and Cognition, Brain Metabolism, and Brain Atrophy in Cognitively Normal Older Adults
Separate research on anticholinergic exposure at midlife echoed those findings. Use of these drugs was linked to greater brain atrophy and a heavier burden of the amyloid plaques and tau tangles that are hallmarks of Alzheimer’s disease. Animal studies have shown that anticholinergic exposure can increase tau pathology, synaptic loss, and neurodegeneration in the hippocampus, the brain’s memory hub.5Alzheimer’s & Dementia: Translational Research & Clinical Interventions. Midlife anticholinergic drug use, risk of Alzheimer’s disease, and brain atrophy in community-dwelling older adults These are worrying signals, but it is worth noting that observing brain changes in people who also happen to take anticholinergics does not settle the direction of causation. Some researchers have raised the possibility that early, undetected cognitive decline could itself lead people to use more of these medications, for example reaching for a sleep aid because dementia-related insomnia is already setting in.
Dose and Duration Are the Key Variables
If there is one takeaway from the research that matters most for everyday decisions, it is that cumulative exposure drives the risk. The large prospective study broke anticholinergic use into tiers based on total standardized daily doses accumulated over a decade. People in the lowest tier, equivalent to taking a standard dose of diphenhydramine daily for about three months total across ten years, showed no statistically significant increase in dementia risk. The hazard ratio was 0.92 at that level, essentially no different from non-users. As total doses climbed through the middle tiers, the risk edged upward but remained modest and not always statistically conclusive. Only at the highest tier, equivalent to more than three years of daily use, did the risk become clearly elevated at about 1.54.6JAMA Network. Cumulative Use of Strong Anticholinergics and Incident Dementia: A Prospective Cohort Study
This means that taking Benadryl a few times a year for seasonal allergies or an occasional sleepless night does not put you in the risk zone the studies are describing. The concern is with chronic, daily or near-daily use that stacks up over years. That pattern is more common than you might expect, particularly among people who use diphenhydramine as a nightly sleep aid and among those on multiple prescription medications with anticholinergic properties that add up.
Why Older Adults Are Especially Vulnerable
The adverse effects of diphenhydramine hit harder at both ends of the age spectrum, in children and in older adults.7PubMed Central. Diphenhydramine: It is time to say a final goodbye For the dementia question specifically, older adults face a confluence of problems. The blood-brain barrier becomes leakier with age, allowing more of the drug to reach the brain. The liver and kidneys clear drugs more slowly, so the same dose lingers longer. Older brains also have less acetylcholine reserve to begin with, so blocking what remains has a proportionally larger effect.
Geriatric medicine guidelines have responded accordingly. The American Geriatrics Society Beers Criteria, which is the most widely used list of medications whose potential harms outweigh their benefits in older adults, flags diphenhydramine and other strongly anticholinergic drugs as ones to avoid when possible.8PubMed Central. Alternative Treatments to Selected Medications in the 2023 American Geriatrics Society Beers Criteria® This does not mean these drugs are banned. It means that before prescribing them to someone over 65, a clinician should weigh whether a safer alternative exists. For allergies, second-generation antihistamines like cetirizine or loratadine carry far less anticholinergic burden. For sleep, the evidence actually favors cognitive behavioral therapy for insomnia over any medication, though melatonin is also considered a lower-risk pharmacological option for older adults.
Does Your Genetic Background Change the Picture
One question researchers have explored is whether carrying the APOE ε4 gene variant, the strongest known genetic risk factor for late-onset Alzheimer’s, amplifies the anticholinergic-dementia link. If it did, people with that variant might need to be even more cautious about these drugs. A population-based study tested this by including an interaction term between anticholinergic drug use and APOE ε4 status. The interaction was not statistically significant, suggesting the elevated dementia risk from anticholinergic exposure did not differ meaningfully between people who carry the gene variant and people who do not.9PubMed Central. Anticholinergic drug burden and risk of incident MCI and dementia – A Population-Based Study In practical terms, this means anticholinergic risk does not seem to single out people with a genetic predisposition. The cumulative exposure pattern appears to raise risk broadly across the population.
The Hidden Problem With Diphenhydramine as a Sleep Aid
Perhaps the most concerning real-world scenario is not the person taking Benadryl for a weeklong allergy flare, but the person reaching for it every night at bedtime. Diphenhydramine is the active ingredient in most over-the-counter sleep aids, including products like ZzzQuil, Tylenol PM, and Advil PM. Many people do not even realize they are taking the same drug as Benadryl. A survey of adults in Saudi Arabia found that younger adults, women, and students were the groups most commonly using diphenhydramine-based sleep aids, and that current users were also more likely to be taking other medications simultaneously, compounding their total anticholinergic load.10Cureus. The Use of Over-the-Counter Sleep Aid Containing Diphenhydramine Hydrochloride Among Saudis
The irony is that diphenhydramine is not even a particularly effective sleep aid beyond the first few nights. Tolerance to its sedating effects develops quickly, often within a week, which pushes people to take higher doses for diminishing returns. Meanwhile, the anticholinergic exposure keeps accumulating. A randomized trial in infants found that diphenhydramine was no more effective than a placebo at reducing nighttime awakenings or improving parental satisfaction with sleep after just one week of use.11JAMA Network. The Trial of Infant Response to Diphenhydramine: The TIRED Study—A Randomized, Controlled, Patient-Oriented Trial While infant sleep physiology is different from adult sleep, the finding illustrates a broader point: the sedative reputation of diphenhydramine outruns the evidence for its actual effectiveness as a sleep solution.
Can the Risk Be Reversed by Stopping
This is one of the most urgent questions people have, and unfortunately, the current research does not give a clean answer. The large prospective study that established the dose-response relationship looked at cumulative use over a ten-year window and then tracked participants forward. It was not designed to test whether people who stopped using anticholinergics saw their risk decline afterward. Some researchers have suggested that the biological changes linked to chronic anticholinergic use, including brain atrophy and reduced metabolism in memory-related regions, might not fully reverse once they are established.4PubMed Central. Association Between Anticholinergic Medication Use and Cognition, Brain Metabolism, and Brain Atrophy in Cognitively Normal Older Adults
That said, stopping or reducing anticholinergic medications often improves short-term cognitive symptoms like confusion and mental fogginess, particularly in older adults. Whether it also reduces long-term dementia risk is a separate and harder question to study. No randomized trial has taken people off anticholinergics and followed them for decades to see if their dementia rates dropped, and such a trial would be logistically difficult. The clinical advice from geriatric specialists is that reducing anticholinergic burden is still a good idea regardless of whether the dementia link is causal, because these drugs cause a range of other problems in older adults, including falls, constipation, urinary retention, and blurred vision.
Anticholinergic Stacking and Medications You Might Not Suspect
One aspect of this topic that rarely makes headlines is the concept of anticholinergic stacking, where a person takes multiple medications that each have modest anticholinergic effects, and the combined burden adds up to something significant. You might take diphenhydramine for sleep, an older antidepressant for mood, and an overactive bladder medication, and each one individually might seem like a small contributor. But their anticholinergic effects are additive. The systematic review of anticholinergic rating scales identified nearly 200 medications with measurable anticholinergic activity, spanning pain relievers, antidepressants, antipsychotics, cardiovascular drugs, and gastrointestinal medications.3PubMed Central. Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: a systematic review
This is why the conversation about Benadryl and dementia should not start and end with Benadryl. If you are taking diphenhydramine for allergies but also on a tricyclic antidepressant and an antispasmodic for irritable bowel syndrome, your total anticholinergic exposure is much higher than any single drug would suggest. Pharmacists can calculate your anticholinergic burden score, and it is a conversation worth having, especially as you get older and medication lists tend to grow.
How This Research Stacks Up Against Other Dementia Risk Factors
Putting anticholinergic drugs in context helps calibrate how worried you should be. The hazard ratios reported in the major studies, around 1.5 for the heaviest users, are meaningful but moderate. For comparison, the APOE ε4 gene variant can raise Alzheimer’s risk by three to twelve times depending on whether you carry one or two copies. Physical inactivity, untreated hearing loss, social isolation, and poorly managed diabetes and hypertension are all well-established dementia risk factors with effect sizes in a similar or larger range than anticholinergic medications. This does not mean anticholinergic exposure is unimportant. It means it is one modifiable factor among several, and probably not the most powerful one for most people.
Where anticholinergic drugs stand out compared to those other risk factors is in how easy they are to address. You cannot change your genetics. Exercising more and managing blood pressure require sustained lifestyle changes. But swapping diphenhydramine for a second-generation antihistamine, or switching to a non-anticholinergic sleep strategy, is something you can do tomorrow. That low barrier to action is part of why this research has gotten so much attention despite the uncertainty about whether the link is truly causal.
Diphenhydramine Use in Younger Adults
Most of the dementia research has focused on people over 65, which raises the question of whether younger adults who use Benadryl regularly should worry. The midlife anticholinergic study found that use of these drugs during middle age was associated with brain atrophy detectable years later, suggesting the exposure window matters and may extend earlier than old age.5Alzheimer’s & Dementia: Translational Research & Clinical Interventions. Midlife anticholinergic drug use, risk of Alzheimer’s disease, and brain atrophy in community-dwelling older adults The data on younger adults specifically are still thin, and there is no study showing that a 30-year-old who takes Benadryl occasionally is meaningfully increasing their dementia risk decades later. But the dose-response nature of the findings suggests that habits formed young can matter if they persist. A 25-year-old who starts using diphenhydramine nightly for sleep and continues that pattern for decades is, in principle, accumulating the kind of exposure the studies flag.
The practical advice for younger adults is less about panic and more about awareness. If you rely on diphenhydramine regularly, whether for allergies or sleep, it is worth exploring alternatives now rather than building a decades-long habit. Second-generation antihistamines work well for most allergy symptoms, and cognitive behavioral therapy for insomnia has strong evidence behind it. Neither carries anticholinergic baggage.